128 INTERVENČNÍ A AKUTNÍ KARDIOLOGIE / Interv Akut Kardiol. 2023;22(3):122-128 / www.iakardiologie.cz PŘEHLEDOVÉ ČLÁNKY / REVIEW ARTICLES Treatment options of in‑stent restenosis: mini review 6. Mehran R, Dangas G, Abizaid AS, et al. Classification and Implications for Long‑Term Outcome. Circulation. 1999;100:1872-8. 7. Shlofmitz E, Case BC, Chen Y, et al. Waksman In‑Stent Restenosis Classification: A Mechanism‑Based Approach to the Treatment of Restenosis. Cardiovasc Revascularization Med [Internet]. 2021;33:62-7. Available from: https://www.sciencedirect.com/science/article/pii/S1553838921002761 8. Dangas GD, Claessen BE, Caixeta A, et al. In‑stent restenosis in the drug‑eluting stent era. J Am Coll Cardiol. 2010;56(23):1897-907. 9. Alexandrescu D‑M, Mitu O, Costache I, et al. Risk factors associated with intra‑stent restenosis after percutaneous coronary intervention. Exp Ther Med. 2021;22(4):1-7. 10. TsiGkas GGG, Karantalis V, Hahalis G, et al. Stent restenosis, pathophysiology and treatment options: A 2010 update. Hell J Cardiol. 2011;52(2):149-57. 11. Kim MS, Dean LS. In‑Stent Restenosis. Cardiovasc Ther. 2011;29(3):190-8. 12. Kuramitsu S, Shirai S, Ando K. Mechanism of in‑stent restenosis after second‑generation drug‑eluting stents (DES): Is it different from bare‑metal stents and first‑generation DES? J Thorac, DiS. 2015;7(12):E599--E602. 13. Nusca A, Viscusi MM, Piccirillo F, et al. In Stent Neo ‑Atherosclerosis: Pathophysiology, Clinical Implications, Prevention, and Therapeutic Approaches. Life. 2022;12(3):1-18. 14. Paramasivam G, Devasia T, Ubaid S, et al. In‑stent restenosis of drug‑eluting stents: clinical presentation and outcomes in a real‑world scenario. Egypt Hear J. 2019;71(1). 15. Magalhaes MA, Minha S, Chen F, et al. Clinical presentation and outcomes of coronary in‑stent restenosis across 3-stent generations. Circ Cardiovasc Interv. 2014;7(6):768-76. 16. Figini F, Louvard Y, Sheiban I. Use of stent enhancement technique during percutaneous coronary intervention – A case series. Heart Int. 2019;13(1):28-31. 17. Figini F, Louvard Y, Sheiban I. Stent Enhancement during Percutaneous Coronary Intervention: Current Role, Technical Tips and Case Examples. Cardiovasc Revascularization Med. 2020;21(1):137-43. 18. Lawton JS, Tamis‑Holland JE, Bangalore S, et al. 2021 ACC/ AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(2):e21-129. 19. Akhtar M, Liu W. Use of intravascular ultrasound vs. optical coherence tomography for mechanism and patterns of in‑stent restenosis among bare metal stents and drug eluting stents. J Thorac, DiS. 2016;8(1):E104-8. 20. Habara M, Terashima M, Nasu K, et al. Morphological differences of tissue characteristics between early, late, and very late restenosis lesions after first generation drug‑eluting stent implantation: An optical coherence tomography study. Eur Heart J Cardiovasc Imaging. 2013;14(3):276-84. 21. Alfonso F, Pérez‑Vizcayno MJ, Dutary J, et al. Implantation of a drug‑eluting stent with a different drug (switch strategy) in patients with drug‑eluting stent restenosis: Results from a prospective multicenter study (RIBS III [restenosis intra‑stent: Balloon angioplasty versus drug‑eluting stent]). JACC Cardiovasc Interv. 2012;5(7):728-37. 22. Giacoppo D, Alfonso F, Xu B, et al. Drug‑Coated Balloon Angioplasty Versus Drug‑Eluting Stent Implantation in Patients With Coronary Stent Restenosis. J Am Coll Cardiol. 2020;75(21):2664-78. 23. Siontis GCM, Stefanini GG, Mavridis D, et al. Percutaneous coronary interventional strategies for treatment of in ‑stent restenosis: a network meta‑analysis. Lancet (London, England). 2015 Aug;386(9994):655-64. 24. Neumann FJ, Sousa‑Uva M, Ahlsson A, et al. 2018 ESC/ EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87-165. 25. Goel SS, Dilip Gajulapalli R, Athappan G, et al. Management of drug eluting stent in‑stent restenosis: A systematic review and meta‑analysis. Catheter Cardiovasc Interv. 2016;87(6):1080-91. 26. Wang G, Zhao Q, Chen Q, et al. Comparison of drug ‑eluting balloon with repeat drug‑eluting stent for recurrent drug‑eluting stent in‑stent restenosis. Coron Artery, DiS. 2019;30(7):473-80. 27. Ali RM, Abdul Kader MASK, Wan Ahmad WA, et al. Treatment of Coronary Drug‑Eluting Stent Restenosis by a Sirolimus- or Paclitaxel‑Coated Balloon. JACC Cardiovasc Interv. 2019;12(6):558-66. 28. Ahmad WAW, Nuruddin AA, Abdul Kader MASK, et al. Treatment of Coronary De Novo Lesions by a Sirolimus- or Paclitaxel‑Coated Balloon. JACC Cardiovasc Interv. 2022;15(7):770-9. 29. Basavarajaiah S, Mitomo S, Nakamura S, et al. Long‑term Outcome following Percutaneous Intervention of Intra‑stent Coronary Occlusion and Evaluating the Different Treatment Modalities. IJC Hear Vasc [Internet]. 2021;34:100803. Available from: https://doi.org/10.1016/j.ijcha.2021.100803 30. Yang J, Mamuti W, Zhang F. Optimal interventional strategy for the treatment of coronary in‑stent restenosis. J Thorac, DiS. 2015;7(10):1669-71. 31. Aoki Y, De Gregorio J. Optimal Approach for Treating In ‑Stent Restenosis. Card Interv Today. 2018;12(3):49-52. 32. Linares Vicente JA, Ruiz Arroyo JR, Lukic A, et al. 5-Year Results of Cutting or Scoring Balloon Before Drug‑Eluting Balloon To Treat in‑Stent Restenosis. REC Interv Cardiol (English Ed. 2022;4(June 2021):12-8. 33. Kufner S, Joner M, Schneider S, et al. Neointimal Modification With Scoring Balloon and Efficacy of Drug‑Coated Balloon Therapy in Patients With Restenosis in Drug‑Eluting Coronary Stents: A Randomized Controlled Trial. JACC Cardiovasc Interv. 2017;10(13):1332-40. 34. Alfonso F, Byrne RA, Rivero F, et al. Current treatment of in‑stent restenosis. J Am Coll Cardiol. 2014;63(24):2659-73. 35. Moscarella E, Ielasi A, Granata F, et al. Long‑term clinical outcomes after bioresorbable vascular scaffold implantation for the treatment of coronary in‑stent restenosis. Circ Cardiovasc Interv. 2016;9(4):1-9. 36. Bossard M, Attinger A, Wolfrum M, et al. Bioresorbable scaffold versus drug coated balloon for treatment of in ‑stent‑restenosis – long‑term outcomes of the randomized ABSORB‑ISR trial. Eur Heart J. 2020;41. 37. Alfonso F, Cuesta J, Pérez‑Vizcayno MJ, et al. Bioresorbable Vascular Scaffolds for Patients With In‑Stent Restenosis: The RIBS VI Study. JACC Cardiovasc Interv [Internet]. 2017;10(18):1841-51. Available from: http://dx.doi.org/10.1016/j.jcin.2017. 06. 064 38. Andras A, Hansrani M, Stewart M, et al. Intravascular brachytherapy for peripheral vascular disease. Cochrane Database Syst Rev. 2014;2014(1). 39. Condado JA, Waksman R, Calderas C, et al. Two‑year follow‑up after intracoronary gamma radiation therapy. Cardiovasc Radiat Med. 1999;1(1):30-5. 40. Megaly M, Glogoza M, Xenogiannis I, et al. Outcomes of intravascular brachytherapy for recurrent drug ‑eluting in‑stent restenosis. Catheter Cardiovasc Interv. 2021;97(1):32-8. 41. Megaly M, Glogoza M, Xenogiannis I, et al. Coronary Intravascular Brachytherapy for Recurrent Coronary Drug‑Eluting Stent In‑Stent Restenosis: A Systematic Review and Meta‑Analysis. Cardiovasc Revascularization Med. 2021;23(xxxx):28-35. 42. Varghese MJ, Bhatheja S, Baber U, et al. Intravascular brachytherapy for the management of repeated multimetal ‑layered drug‑eluting coronary stent restenosis. Circ Cardiovasc Interv. 2018;11(10):1-8. 43. Wong B, El‑Jack S, Newcombe R, et al. Shockwave Intravascular Lithotripsy for Calcified Coronary Lesions: First Real‑World Experience. J Invasive Cardiol. 2019 Mar;31(3):46-8. 44. Morabito G, Tripolino C, Tassone EJ, et al. Case of Stent Under‑Expansion due to Calcified Plaque Treated with Shockwave Lithoplasty. Cardiol. 2018;141(2):75-7. 45. Gulati AS. Interventional Cardiology Coronary stent fracture and in‑stent restenosis due to severe calcification treated with shockwave coronary intravascular lithotripsy with drug eluting balloon. 2022;189-93. 46. Alfonso F, Bastante T, Antuña P, et al. Coronary Lithoplasty for the Treatment of Undilatable Calcified De Novo and In‑Stent Restenosis Lesions. JACC Cardiovasc Interv. 2019;12(5):497-9. 47. Rawlins J, Din JN, Talwar S, et al. Coronary intervention with the excimer laser: Review of the technology and outcome data. Interv Cardiol Rev Res Resour. 2016;11(1):27-32. 48. Fukui T. Management of acute aortic dissection and thoracic aortic rupture. J Intensive Care. 2018;6(1):1-8. 49. Gupta T, Weinreich M, Greenberg M, et al. Rotational atherectomy: A contemporary appraisal. Interv Cardiol Rev Res Resour. 2019;14(3):182-9. 50. Abdel‑Wahab M, Toelg R, Byrne RA, et al. High‑speed rotational atherectomy versus modified balloons prior to drug‑eluting stent implantation in severely calcified coronary lesions: The randomized prepare‑CALC trial. Vol. 11, Circulation: Cardiovascular Interventions. 2018. 51. Moustapha A, Assali AR, Sdringola S, et al. Percutaneous and surgical interventions for in‑stent restenosis: Long ‑term outcomes and effect of diabetes mellitus. J Am Coll Cardiol. 2001;37(7):1877-82. 52. Ţintoiu IC, Underwood MJ, Cook SP, et al. Coronary graft failure: State of the art. Coron Graft Fail State Art. 2016;1-758. 53. Schömig A, Kastrati A, Wessely R. Prevention of restenosis by systemic drug therapy: Back to the future? Circulation. 2005;112(18):2759-61. 54. Hausleiter J, Kastrati A, Mehilli J, et al. Randomized, double‑blind, placebo‑controlled trial of oral sirolimus for restenosis prevention in patients with in‑stent restenosis: The oral sirolimus to inhibit recurrent in‑stent stenosis (OSIRIS) trial. Circulation. 2004;110(7):790-5.
RkJQdWJsaXNoZXIy NDA4Mjc=